Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study

Dreno, B; Ribas, A; Larkin, J; Ascierto, PA; Hauschild, A; Thomas, L; Grob, JJ; Koralek, DO; Rooney, I; Hsu, JJ; McKenna, EF; McArthur, GA

Dreno, B (reprint author), Nantes Univ, Univ Hosp, CHU Nantes, Dept Dermato Cancerol, Pl Alexis Ricordeau, F-44093 Nantes 01, France.

ANNALS OF ONCOLOGY, 2017; 28 (5): 1137

Abstract

Background: In the coBRIM phase III trial, the addition of cobimetinib, an MEK inhibitor, to vemurafenib, a BRAF inhibitor, significantly improved pro......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索